EUVIMEDEUVIMED entdecken
Open Access

Fructose-1,6-bisphosphatase is a nonenzymatic safety valve that curtails AKT activation to prevent insulin hyperresponsiveness

Li Gu, Yahui Zhu, Kosuke Watari, Maiya Lee, Junlai Liu, Sofia Perez, Melinda Thai, Joshua E Mayfield, Bichen Zhang, Karina Cunha E Rocha, Fuming Li, Laura C Kim und 11 weitere

Cell Metabolism · 2023-06 · 35 (6) · 1009-1021.e9

DOI: 10.1016/j.cmet.2023.03.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Metabolism, 2023-06. Verfasst von Li Gu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California, San D…. Hauptthemen laut MEDLINE: Fructose, Hypoglycemia. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulin inhibits gluconeogenesis and stimulates glucose conversion to glycogen and lipids. How these activities are coordinated to prevent hypoglycemia and hepatosteatosis is unclear. Fructose-1,6-bisphosphatase (FBP1) is rate controlling for gluconeogenesis. However, inborn human FBP1 deficiency does not cause hypoglycemia unless accompanied by fasting or starvation, which also trigger paradoxical hepatomegaly, hepatosteatosis, and hyperlipidemia. Hepatocyte FBP1-ablated mice exhibit identical fasting-conditional pathologies along with AKT hyperactivation, whose inhibition reversed hepatomegaly, hepatosteatosis, and hyperlipidemia but not hypoglycemia. Surprisingly, fasting-mediated AKT hyperactivation is insulin dependent. Independently of its catalytic activity, FBP1 prevents insulin hyperresponsiveness by forming a stable complex with AKT, PP2A-C, and aldolase B (ALDOB), which specifically accelerates AKT dephosphorylation. Enhanced by fasting and weakened by elevated insulin, FBP1:PP2A-C:ALDOB:AKT complex formation, which is disrupted by human FBP1 deficiency mutations or a C-terminal FBP1 truncation, prevents insulin-triggered liver pathologies and maintains lipid and glucose homeostasis. Conversely, an FBP1-derived complex disrupting peptide reverses diet-induced insulin resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FructoseHypoglycemiaHumansMiceAnimalsFructose-BisphosphataseProto-Oncogene Proteins c-aktInsulinHepatomegalyGlucose

Stichwörter der Autor:innen

AKTFBP1hepatomegalyhepatosteatosis

Substanzen

FructoseFructose-BisphosphataseProto-Oncogene Proteins c-aktInsulinGlucose

Autor:innen und Institutionen

  • Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
  • School of Medicine, Chongqing University, Chongqing 400030, China.
  • Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093, USA.
  • Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
  • Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA…
  • Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Department of Surgery, University of California, San Diego, La Jolla, CA 92093, USA.

Förderung

  • NIDDK NIH HHS
  • NCI NIH HHS
  • NICHD NIH HHS
  • NIEHS NIH HHS
  • NIAAA NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health
  • University of Pennsylvania

Zitieren

APA

Gu, L., Zhu, Y., Watari, K., Lee, M., Liu, J., Perez, S., Thai, M., Mayfield, J. E., Zhang, B., Cunha E Rocha, K., Li, F., Kim, L. C., Jones, A. C., Wierzbicki, I. H., Liu, X., Newton, A. C., Kisseleva, T., Lee, J. H., Ying, W., …, & Karin, M. (2023). Fructose-1,6-bisphosphatase is a nonenzymatic safety valve that curtails AKT activation to prevent insulin hyperresponsiveness. Cell Metabolism, 35(6), 1009-1021.e9. https://doi.org/10.1016/j.cmet.2023.03.021

Vancouver

Gu L, Zhu Y, Watari K, Lee M, Liu J, Perez S, et al. Fructose-1,6-bisphosphatase is a nonenzymatic safety valve that curtails AKT activation to prevent insulin hyperresponsiveness. Cell Metabolism. 2023;35(6):1009-1021.e9. doi:10.1016/j.cmet.2023.03.021

BibTeX
@article{Gu2023,
  author = {Gu, Li and Zhu, Yahui and Watari, Kosuke and Lee, Maiya and Liu, Junlai and Perez, Sofia and Thai, Melinda and Mayfield, Joshua E and Zhang, Bichen and Cunha E Rocha, Karina and Li, Fuming and Kim, Laura C and Jones, Alexander C and Wierzbicki, Igor H and Liu, Xiao and Newton, Alexandra C and Kisseleva, Tatiana and Lee, Jun Hee and Ying, Wei and Gonzalez, David J and Saltiel, Alan R and Simon, M Celeste and Karin, Michael},
  title = {Fructose-1,6-bisphosphatase is a nonenzymatic safety valve that curtails AKT activation to prevent insulin hyperresponsiveness},
  journal = {Cell Metabolism},
  year = {2023},
  volume = {35},
  number = {6},
  pages = {1009--1021.e9},
  doi = {10.1016/j.cmet.2023.03.021}
}
Kostenlos starten →